Table 1 Patient demographics and clinical overview of main trial group by dose level cohort
Variable | Cohort 1 | Cohort 2 | Cohort 3 | Total | Control seta |
|---|---|---|---|---|---|
agenT-797 dose level (cells) | 100 × 106 | 300 × 106 | 1000 × 106 | -- | |
Patients dosed (n) | 3 | 4 | 13 | 20 | 20 |
Age | |||||
Median (range) | 67 (66–77) | 71.5 (64–75) | 62 (26–75) | 66.5 (26–77) | 70 (51–87) |
Sex, n (%) | |||||
Male | 2 (66.7) | 1 (25.0) | 7 (53.8) | 10 (50.0) | NA |
Female | 1 (33.3) | 3 (75.0) | 6 (46.2) | 10 (50.0) | NA |
BMI, average (range) | 32.8 (23.2–42.9) | 28.5 (16.6–40.2) | 32.6 (19.4–51.7) | 31.8 (16.6–51.7) | 30.3 (18.5–46) |
Prior and concomitant COVID-19 medication, n (%) | |||||
Received steroids (dexamethasone) | 3 (100.0) | 4 (100.0) | 11 (84.6) | 18 (90.0) | 11 (55.0) |
Received immunomodulatory agents (tocilizumab, baricitinib) | 1 (33.3) | 2 (50.0) | 9 (69.2) | 12 (60.0) | 5 (25.0) |
Received Remdesivir | 2 (66.7) | 4 (100.0) | 11 (84.6) | 17 (85.0) | 17 (85.0) |
Patient disposition, n (%) | |||||
Early Discontinuation | 0 | 1 (25.0) | 5 (38.5) | 6 (30.0) | -- |
Death | 0 | 1 (25.0) | 5 (38.5) | 6 (30.0) | 19 (90.0) |
